Psychoactive compounds as multifactorial protection factors against COVID-19

doi:10.1007/s11845-020-02346-9

Comment

. 2021 May;190(2):849-850.

doi: 10.1007/s11845-020-02346-9. Epub 2020 Aug 18.

Psychoactive compounds as multifactorial protection factors against COVID-19

Hervé Javelot^{1

2}, Luisa Weiner^{3

4}, Julien Petrignet⁵, Guillaume Meyer^{6

7}, Jeanne Briet⁸, Wissam El-Hage^{9

10}, Coraline Hingray^{11

12}

Affiliations

¹ Établissement Public de Santé Alsace Nord, Brumath, France. herve.javelot@ch-epsan.fr.
² Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg, France. herve.javelot@ch-epsan.fr.
³ Clinique de Psychiatrie, CHU de Strasbourg, Strasbourg, France.
⁴ Laboratoire de Psychologie des Cognitions, Université de Strasbourg, Strasbourg, France.
⁵ Laboratoire Synthèse et Isolement de Molécules BioActives (SIMBA, EA 7502), , Faculté des Sciences et Techniques, Université de Tours, Tours, France.
⁶ Service Pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France.
⁷ Service Pharmacie, CHU de de Strasbourg, Strasbourg, France.
⁸ Service Pharmacie, Centre Hospitalier de Montceau, Montceau-les-Mines, France.
⁹ UMR 1253, iBrain, Université de Tours, CHRU de Tours, INSERM, Tours, France.
¹⁰ Centre Expert Dépression Résistante, Fondation FondaMental, Tours, France.
¹¹ Pôle Hospitalo-Universitaire de Psychiatrie d'Adultes du Grand Nancy, Centre Psychothérapique de Nancy, Laxou, France.
¹² Département de Neurologie, CHU de Nancy, Nancy, France.

PMID: 32812114
PMCID: PMC7433988
DOI: 10.1007/s11845-020-02346-9

Comment

Psychoactive compounds as multifactorial protection factors against COVID-19

Hervé Javelot et al. Ir J Med Sci. 2021 May.

. 2021 May;190(2):849-850.

doi: 10.1007/s11845-020-02346-9. Epub 2020 Aug 18.

Authors

Hervé Javelot^{1

2}, Luisa Weiner^{3

4}, Julien Petrignet⁵, Guillaume Meyer^{6

7}, Jeanne Briet⁸, Wissam El-Hage^{9

10}, Coraline Hingray^{11

12}

Affiliations

¹ Établissement Public de Santé Alsace Nord, Brumath, France. herve.javelot@ch-epsan.fr.
² Laboratoire de Toxicologie et Pharmacologie Neuro Cardiovasculaire, Université de Strasbourg, Strasbourg, France. herve.javelot@ch-epsan.fr.
³ Clinique de Psychiatrie, CHU de Strasbourg, Strasbourg, France.
⁴ Laboratoire de Psychologie des Cognitions, Université de Strasbourg, Strasbourg, France.
⁵ Laboratoire Synthèse et Isolement de Molécules BioActives (SIMBA, EA 7502), , Faculté des Sciences et Techniques, Université de Tours, Tours, France.
⁶ Service Pharmacie, Établissement Public de Santé Alsace Nord, Brumath, France.
⁷ Service Pharmacie, CHU de de Strasbourg, Strasbourg, France.
⁸ Service Pharmacie, Centre Hospitalier de Montceau, Montceau-les-Mines, France.
⁹ UMR 1253, iBrain, Université de Tours, CHRU de Tours, INSERM, Tours, France.
¹⁰ Centre Expert Dépression Résistante, Fondation FondaMental, Tours, France.
¹¹ Pôle Hospitalo-Universitaire de Psychiatrie d'Adultes du Grand Nancy, Centre Psychothérapique de Nancy, Laxou, France.
¹² Département de Neurologie, CHU de Nancy, Nancy, France.

PMID: 32812114
PMCID: PMC7433988
DOI: 10.1007/s11845-020-02346-9

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Comment on

Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders.
Villoutreix BO, Beaune PH, Tamouza R, Krishnamoorthy R, Leboyer M. Villoutreix BO, et al. Drug Discov Today. 2020 Aug;25(8):1287-1290. doi: 10.1016/j.drudis.2020.06.022. Epub 2020 Jun 25. Drug Discov Today. 2020. PMID: 32593662 Free PMC article. No abstract available.

Cited by

Psychotropics and COVID-19: An analysis of safety and prophylaxis.
Javelot H, Straczek C, Meyer G, Gitahy Falcao Faria C, Weiner L, Drapier D, Fakra E, Fossati P, Weibel S, Dizet S, Langrée B, Masson M, Gaillard R, Leboyer M, Llorca PM, Hingray C, Haffen E, Yrondi A. Javelot H, et al. Encephale. 2021 Dec;47(6):564-588. doi: 10.1016/j.encep.2021.08.002. Epub 2021 Sep 2. Encephale. 2021. PMID: 34548153 Free PMC article.
Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review.
Shafiekhani M, Dehghani A, Shahisavandi M, Nabavizadeh SA, Kabiri M, Hassani AH, Haghpanah A. Shafiekhani M, et al. Ther Adv Urol. 2021 Sep 28;13:17562872211046794. doi: 10.1177/17562872211046794. eCollection 2021 Jan-Dec. Ther Adv Urol. 2021. PMID: 34603508 Free PMC article. Review.
Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19.
Hoertel N, Sánchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C, Lemogne C, Airagnes G, Paris N, Daniel C, Gramfort A, Lemaitre G, Bernaux M, Bellamine A, Beeker N, Limosin F; AP-HP/Universities/INSERM COVID-19 Research Collaboration and AP-HP COVID CDR Initiative. Hoertel N, et al. Clin Drug Investig. 2021 Mar;41(3):221-233. doi: 10.1007/s40261-021-01001-0. Epub 2021 Feb 9. Clin Drug Investig. 2021. PMID: 33559821 Free PMC article.

References

1. Villoutreix BO, Beaune PH, Tamouza R, Krishnamoorthy R, Leboyer M. Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders. Drug Discov Today. 2020;S1359–6446(20):30250–30256. doi: 10.1016/j.drudis.2020.06.022. - DOI - PMC - PubMed
1. Plaze M, Attali A, Petit AC, et al. Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study. Encephale. 2020;46(3S):S35–S39. doi: 10.1016/j.encep.2020.04.010. - DOI - PMC - PubMed
1. Psychiatry SE, COVID-19: the role of chlorpromazine [published online ahead of print Jun 15. Can J Psychiatr. 2020;2020:706743720934997. doi: 10.1177/0706743720934997. - DOI
1. Briet J, Javelot H, Heitzmann E, Weiner L, Lameira C, D’Athis P, Corneloup M, Vailleau JL. The anticholinergic impregnation scale: towards the elaboration of a scale adapted to prescriptions in French psychiatric settings. Therapie. 2017;72(4):427–437. doi: 10.1016/j.therap.2016.12.010. - DOI - PubMed
1. Farsalinos K, Niaura R, Le Houeze J, et al. Editorial: nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020;7:658–663. doi: 10.1016/j.toxrep.2020.04.012. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Villoutreix BO, Beaune PH, Tamouza R, Krishnamoorthy R, Leboyer M. Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders. Drug Discov Today. 2020;S1359–6446(20):30250–30256. doi: 10.1016/j.drudis.2020.06.022. - DOI - PMC - PubMed

[2] Villoutreix BO, Beaune PH, Tamouza R, Krishnamoorthy R, Leboyer M. Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders. Drug Discov Today. 2020;S1359–6446(20):30250–30256. doi: 10.1016/j.drudis.2020.06.022. - DOI - PMC - PubMed

[3] Plaze M, Attali A, Petit AC, et al. Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study. Encephale. 2020;46(3S):S35–S39. doi: 10.1016/j.encep.2020.04.010. - DOI - PMC - PubMed

[4] Plaze M, Attali A, Petit AC, et al. Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study. Encephale. 2020;46(3S):S35–S39. doi: 10.1016/j.encep.2020.04.010. - DOI - PMC - PubMed

[5] Psychiatry SE, COVID-19: the role of chlorpromazine [published online ahead of print Jun 15. Can J Psychiatr. 2020;2020:706743720934997. doi: 10.1177/0706743720934997. - DOI

[6] Psychiatry SE, COVID-19: the role of chlorpromazine [published online ahead of print Jun 15. Can J Psychiatr. 2020;2020:706743720934997. doi: 10.1177/0706743720934997. - DOI

[7] Briet J, Javelot H, Heitzmann E, Weiner L, Lameira C, D’Athis P, Corneloup M, Vailleau JL. The anticholinergic impregnation scale: towards the elaboration of a scale adapted to prescriptions in French psychiatric settings. Therapie. 2017;72(4):427–437. doi: 10.1016/j.therap.2016.12.010. - DOI - PubMed

[8] Briet J, Javelot H, Heitzmann E, Weiner L, Lameira C, D’Athis P, Corneloup M, Vailleau JL. The anticholinergic impregnation scale: towards the elaboration of a scale adapted to prescriptions in French psychiatric settings. Therapie. 2017;72(4):427–437. doi: 10.1016/j.therap.2016.12.010. - DOI - PubMed

[9] Farsalinos K, Niaura R, Le Houeze J, et al. Editorial: nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020;7:658–663. doi: 10.1016/j.toxrep.2020.04.012. - DOI - PMC - PubMed

[10] Farsalinos K, Niaura R, Le Houeze J, et al. Editorial: nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020;7:658–663. doi: 10.1016/j.toxrep.2020.04.012. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Psychoactive compounds as multifactorial protection factors against COVID-19

Affiliations

Psychoactive compounds as multifactorial protection factors against COVID-19

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical